LENZ
LENZ Therapeutics Inc.

1,190
Mkt Cap
$655.15M
Volume
1.7M
52W High
$50.40
52W Low
$16.54
PE Ratio
-10.90
LENZ Fundamentals
Price
$23.25
Prev Close
$22.96
Open
$22.31
50D MA
$38.39
Beta
1.06
Avg. Volume
1.17M
EPS (Annual)
-$2.34
P/B
3.39
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Insider Buying: LENZ Therapeutics (NASDAQ:LENZ) CFO Acquires 2,198 Shares of Stock
LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) CFO Daniel Chevallard acquired 2,198 shares of LENZ Therapeutics stock in a transaction that occurred on Friday, November 7th. The stock was...
MarketBeat·3h ago
News Placeholder
More News
News Placeholder
Brokers Set Expectations for LENZ Q3 Earnings
LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Equities research analysts at HC Wainwright issued their Q3 2026 earnings per share estimates for shares of LENZ Therapeutics in a note issued to...
MarketBeat·14h ago
News Placeholder
William Blair Predicts Weaker Earnings for LENZ Therapeutics
LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Equities researchers at William Blair decreased their FY2025 earnings per share estimates for LENZ Therapeutics in a report released on...
MarketBeat·17h ago
News Placeholder
LENZ Therapeutics (NASDAQ:LENZ) Announces Earnings Results
LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus...
MarketBeat·2d ago
News Placeholder
LENZ Therapeutics (NASDAQ:LENZ) Shares Gap Down - Time to Sell?
LENZ Therapeutics (NASDAQ:LENZ) Shares Gap Down - Here's Why...
MarketBeat·3d ago
News Placeholder
LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Beats Revenue Estimates
LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of +11.94% and +92.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
LENZ Therapeutics, Inc. (LENZ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for LENZ Therapeutics, Inc. (LENZ), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Zacks·10d ago
News Placeholder
LENZ Therapeutics, Inc. (LENZ) Upgraded to Buy: What Does It Mean for the Stock?
LENZ Therapeutics, Inc. (LENZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·18d ago
News Placeholder
LENZ Therapeutics, Inc. (LENZ) is a Great Momentum Stock: Should You Buy?
Does LENZ Therapeutics, Inc. (LENZ) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·4mo ago
News Placeholder
Does LENZ Therapeutics, Inc. (LENZ) Have the Potential to Rally 30.86% as Wall Street Analysts Expect?
The consensus price target hints at a 30.9% upside potential for LENZ Therapeutics, Inc. (LENZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·4mo ago

Latest LENZ News

View

Advertisement|Remove ads.

Advertisement|Remove ads.